OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today outlined its ambition for above-market, double-digit revenue growth of its Growth and Emerging Markets Business Unit (“GEM BU”). The revenue goal of JPY 1 trillion (approximately US$9 billion) by FY2030 represents more than doubling of current revenues in GEM BU. This potential growth will be primarily driven by a balanced geographical focus and targeted portfolio investments in the Company’s highly innovative 14 Global Brands and Wave 1 pipeline assets.
“Building upon Takeda’s global vision to bring long-term value to patients, society and shareholders, we have sharpened our regional strategy to deliver healthcare in geographies that include 85% of the world’s population. As a purpose-led, patient-centric and values-based company, our portfolio combines innovative therapies with the right degree of scale to be competitive. Together with attractive market fundamentals and an executive team equipped to deliver strong business performance, we are committed to delivering sustainable revenue growth while increasing patient access to our life-saving and life-transforming treatments,” said Ricardo Marek, President of Growth & Emerging Markets Business Unit at Takeda.
With 95%3 of GEM BU’s current revenues coming from innovative treatments aligned with the company’s five key business areas, GEM BU has an ambition to outpace forecasted market revenue growth for the region over the next ten years. As a vast geographic area with a combined population of 6.5 billion, the Emerging Markets region presents significant growth opportunities in unmet patient needs across key therapy areas, which we believe can be achieved by a globally-aligned ‘access-first’ strategy.
“Emerging Markets will be a key source of revenue and momentum for Takeda over the next decade, with a strategy aligned to our global innovation focus,” said Costa Saroukos, Takeda chief financial officer. “Through targeted investments in the portfolio and key markets, we expect growth of the GEM BU to outpace the market for specialized, innovative treatments, as we expand our 14 global brands and launch our Wave 1 pipeline assets in the region.”
Takeda’s GEM BU is targeting expansion in high growth markets such as Brazil, China and India. These markets are expected to provide strong platforms for continued growth of existing brands and upcoming launches of our Wave 1 pipeline assets across key therapeutic areas. China in particular is expected to be a significant growth driver for Takeda on a regional and global level, with the potential to deliver revenue growth at a compound annual growth rate of over 20% over the next five years.1
Takeda’s innovative R&D engine is also expected to add potentially transformative therapies to the GEM BU’s current portfolio. Among the Wave 1 pipeline assets, Takeda’s dengue vaccine candidate (TAK-003), developed to address the 390 million global dengue infections every year, is projected to be a significant growth driver for the region, with the majority of projected revenues coming from GEM BU.
For sustainable growth in Emerging Markets, Takeda is committed to ensuring that patients get continued access to innovative medicines. This includes strengthening local health systems and prioritizing sustainable approaches to commercial operations. The recently published 2021 Access to Medicine (AtM) Index has ranked Takeda first in Governance of Access, highlighting its work in the strengthening of health systems and compliance.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in healthcare in approximately 80 countries. For more information, visit https://www.takeda.com.
About Takeda’s Growth and Emerging Markets Business Unit
Globally, Takeda operates from four regions: Japan, the U.S., Europe & Canada (EUCAN), and Growth & Emerging Markets (GEM). Led from its regional offices in Singapore, GEM BU has presence in almost 50 geographies that include Brazil, China and Russia. These three countries, in addition to three Area operations* with hubs in South America, the Middle East, and Asia Pacific, are of particular focus as part of the Region’s ambition to deliver sustainable, profitable growth via commercial activities, and increase patient impact via Takeda’s commitments to expand its global Access to Medicines strategy.
*The three Areas in GEM are:
ICMEA - India, CIS (excluding Russia), the Middle East and Africa led from Dubai, UAE
SAM - South Cone, Andean and Mexico led from Buenos Aires, Argentina
APAC - Asia Pacific led from Singapore
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
1 Includes incremental revenue not adjusted for Probability of Technical Success (PTS) and is not a “forecast” or “target” figure. PTS applies to the probability that a given clinical trial/study will be successful based on pre-defined endpoints, feasibility and other factors and regulatory bodies will grant approval.
2 Based on FY20 Plan rates (1 USD = 111 JPY)
3 Adjusted for divested assets; based on FY2019 underlying growth